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Abstract
Background: The incidence and burden of depressive disorders are increasing in South Korea. There are many
differences between pharmaceutically treated depression (PTD) and treatment-resistant depression (TRD), including
the economic consequences; however, to our knowledge, the economic burden of depression is understudied in
South Korea. Therefore, the objective of the present study was to calculate the different economic costs of PTD and
TRD in South Korea, specifically by comparing several aspects of medical care.
Methods: This study comprised patients aged 18 and over who were newly prescribed antidepressants for more
than 28 days with a depression code included from January 1, 2012, to December 31, 2012, by the Health Insurance
Review and Assessment Service (HIRA). TRD was classified as more than two antidepressant regimen failures in PTD
patients. The cost was calculated based on the cost reflected on the receipt registered with HIRA.
Results: Of the 834,694 patients with PTD, 34,812 patients (4.17%) were converted to TRD. The cost of medical care
for TRD (6,610,487 KRW, 5881 USD) was approximately 5 times higher than the cost of non-TRD (1,273,045 KRW,
1133 USD) and was significantly higher for patients with or without depression and suicide codes. Medical
expenses incurred by non-psychiatrists were roughly 1.7 times higher than those incurred by psychiatrists.
Conclusions: TRD patients had significantly higher healthcare costs than PTD patients. Identifying these financial
aspects of care for depression can help to establish a more effective policy to reduce the burden on mentally ill
patients.
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Background
Globally, major depressive disorder is an increasingly com-
mon disease with more than 300 million people suffering
from it, according to the World Health Organization [1].
The one year incidence of major depression is approxi-
mately 5%, but can vary up to 10% in western European
countries [2]. Moreover, the one year incidence of mood
disorders in the United States is 9.5%, while in Asian coun-
tries it is much lower (Japan: 2.9%; South Korea: 3.6%) [3–
5]. As a result, both the prevalence and social costs of de-
pression are increasing, posing an important problem. In
2000, depression was determined to be one of the biggest
causes of non-fatal burden [6]. In Germany, the direct cost
of depression, per person, increased to 783 EUR (893.17
USD) in 2016 from 458.9 EUR (523.47 USD) in 2013 [7, 8].
Additionally, in Sweden, the total burden of depression al-
most doubled from 1997 to 2005 [9], which has also been
reported in the United States (from 173.2 billion USD in
2005 to 210.5 billion USD in 2010) [10]. The economic
burden of depression in Switzerland is approximately 8 bil-
lion EUR (9.13 billion USD) [11]; however, this figure is
relatively underestimated in East Asia, as the direct costs of
depression were cited as 8.09 billion RMB (0.99 billion
USD) in 2007 in China [12] and 180 billion JPY (1.63 billion
USD) in 2005 in Japan [13].
In some instances of depression, there are no symptom-
atic improvements with standard treatments. When the re-
sponse to at least two different classes of antidepressants
for an adequate period of time and dose is poor, these pa-
tients are defined as having treatment resistant depression
(TRD), which has an incidence of approximately 15–20%
within cases of depression [14, 15]. TRD patients are
known to frequently use antipsychotics, non-
pharmaceutical treatments, and inpatient treatment [16]
and are often associated with multiple episodes of depres-
sion, decreased quality of life, and increased mortality [17].
Moreover, from a social standpoint, the economic burden
of TRD is increasing worldwide, which is becoming prob-
lematic [18]. Compared to non-TRD patients, costs of TRD
have increased by 29.3, 81, and 57% in the United States
[19], Brazil [20], and Japan [21], respectively. Although
there are large differences in costs per country, there is a
paucity of studies determining the burden of depression in
South Korea. To our knowledge, in 2012, the only study of
its kind was conducted, which found that in South Korea,
the direct health care costs of depression were 152.6 million
USD, while the morbidity costs comprised the largest por-
tion of the global burden of depression [22].
Through a national cohort, we have recently uncovered
the epidemiology and characteristics of TRD in South
Korea. We found that the incidence of TRD in Korea was
11.5 per 100 people in 2012. TRD accounted for roughly
0.08% of the total adult population and 4.17% of patients
with depression. TRD patients required a longer duration
of treatment and presented more comorbidities than non-
TRD patients; however, the economic burden of depres-
sion in this region remains unclear [23]. Therefore, the
aim of the present study was to investigate the economic
burden of depression in South Korea. The first objective
was to analyze the cost of depression using data from the
National Health Insurance (NHI) in South Korea. The
second objective was to compare the direct costs of TRD
and non-TRD through several aspects such as risk of sui-
cide, age, and the specialty of the doctor. We hypothesized
that there would be higher costs associated with TRD than
non-TRD, and that within the TRD group, there would be
higher expenses due to the increased rates of suicide, age,
and non-psychiatric care. Therefore, in the present study,
by analyzing the differences in costs between TRD and
non-TRD, we aimed to better understand the socioeco-




In South Korea, there is a unique NHI that covers 98%
of the population [24]. They developed a claiming sys-
tem called the Health Insurance Review and Assessment
Service (HIRA), which contains data from 90% of Ko-
reans [25]. Moreover, researchers can request statistical
data from HIRA to conduct studies [24]. In the present
study, medical records and expenses via receipts were
collected from HIRA from between January 1, 2011, to
December 31, 2015. As no personal information was col-
lected, no consent was required. The protocol of the
present study was exempt from review by the Institu-
tional Review Board (IRB) of Seoul National University
Hospital and the Seoul National University College of
Medicine (IRB number: 1611–056-807).
Definitions of pharmaceutically treated depression (PTD)
and TRD
PTD is characterized by successful treatment of depres-
sion with prescribed antidepressants. Therefore, the pa-
tients were placed in the PTD group when the diagnosis
of depression and prescription of antidepressants were
made within 30 days of each other, similar to the defin-
ition in studies using national registry data [21, 26]. In the
PTD patients, the first day of antidepressant prescription
was considered the index date and the PTD episode ended
when the patient was no longer prescribed antidepressants
for 120 days or more and no longer met diagnostic cri-
teria. In cases of multiple PTD episodes in a single patient,
only the first episode was assessed.
In this study, patients were considered to have TRD
when two or more antidepressants were ineffective in
treating their depression, same as the definition in previ-
ous studies. For the definition of TRD, most studies
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focused on the lack of response to drugs, and clinical defi-
nitions were virtually impossible in studies using national
registry data [27]. Therefore, as in other studies in Japan,
Taiwan, and the United States, TRD was defined as the
subsequent administration of a third antidepressant pre-
scription, and the end date of the second prescription was
the index date of TRD [21, 26, 28]. Detailed criteria for
the definitions of PTD and TRD have been described in a
previous study publishied in 2019 [23].
Medication regimen
The duration of medication was set to be 15 days in
studies from Japan and 30 days in studies from the
United States [21, 28]. One regimen was defined as the
continuous use of one antidepressant or antipsychotic
agent for more than 28 days during the PTD period in
this study, based on a Taiwanese study [26]. This is
because a 15-day period is too short to confirm the
response to antidepressants [29]. The first regimen had
to be started with antidepressants, while the second one
could be started with another type of drug. Moreover,
when the drug was discontinued for at least 30 days dur-
ing the PTD period, it was considered to be the end of
the regimen. Patients were considered to be in remission
if at the end of the regimen, there had been no anti-
depressant or antipsychotic prescription for 120 days. A
minimum dose criterion was set for antipsychotic regi-
mens, but not for antidepressant regimens, because anti-
psychotics may be used for other purposes, such as sleep
control or antidepressant effects [30]. The failure of one
regimen was defined as a change to another regimen
and when the same drug was used for more than 90
days, it was considered to be effective. Specific medica-
tion regimens and the minimal dose for drugs have been
previously described [23].
Study populations
Of the available medical records since 2011, data were
collected from those who had been prescribed antide-
pressants more than once since 2012 and were over the
age of 18 at the time of prescription. The present study
excluded patients who had antidepressant prescriptions
for at least 4 months after the start of the study, as we
aimed to investigate new depressive episodes.
Subjects were excluded if they received an exclusionary
diagnosis during the study period or in the case of death.
Exclusionary diagnoses included psychotic (schizophrenia
[F20], schizotypal disorder [F21], persistent delusional dis-
orders [F22], acute and transient psychotic disorders [F23],
schizoaffective disorder [F25], or other nonorganic psych-
otic disorders [F28]) and neurocognitive disorders (Alzhei-
mer’s disease [F00], vascular dementia [F01], dementia in
other diseases classified elsewhere [F02], or unspecific
dementia [F03]). Additionally, manic episodes (F30) and
bipolar affective disorder (F31) were excluded if they were
the primary diagnosis; in South Korea, there are often cases
where the diagnosis is made without a clear manic episode
so mood stabilizers can be prescribed.
A portion of the PTD patients were prescribed antide-
pressants at the end of the observation period of the
present study. As their episode was still ongoing, it was
not possible to distinguish between non-TRD and TRD
diagnoses; however, we recognized that TRD accounts
for approximately 4% of cases, so we included them in
the non-TRD group.
Medical costs
In the present study, the direct medical costs were
assessed based on costs of prescriptions and those
reflected by receipts registered with HIRA; however, if pa-
tients visited several departments or hospitals on the same
day, it was registered as one receipt in HIRA. Receipts
generated at the hospital included the costs of the pre-
scribed medication, counseling, and other psychological
and blood tests that may have been prescribed by the doc-
tor. As a result, if the medical expenses were calculated as
a sum of the costs reflected by the receipts, it was more
likely to be overestimated. Therefore, through the details
of each receipt, the circumstances in which the receipt
was issued could be inferred. For example, when the re-
ceipts with codes indicating depression were selected sep-
arately and the costs were calculated, the medical
expenses related to depression could be estimated.
For each receipt, the amounts paid by the health insur-
ance corporation and the individual were charged separ-
ately. Therefore, in the present study, the total amount was
summed to measure the overall direct medical expenses.
Medical expenses were calculated with the receipts
from January 1 to December 31, 2012. The insurance
system in Korea had refund system for expenses that are
considered overcharged. Refunds are usually made
within 2 to 3 years of payment. Therefore, the cost in
2012, which is estimated to have ended the refund, could
be the most accurate. The exchange rate to USD pre-
sented in this study was the rate in 2019.
Variables
Depression and suicide codes
The diagnosis of major depressive disorder was defined
as PTD when an antidepressant was prescribed, while
the diagnostic codes were limited to F32, F33, and F34.1.
Cases of suicide were defined when the patient received
a diagnostic code containing “self-harm” and related to
the trauma associated with the suicide attempt. The
trauma associated with suicide attempts included all the
codes related to laceration to the wrist (S60, S61, S69),
falling off a structure (i.e., building, cliff; W13, W15,
W19), hanging (W75, W76), drowning (W65–74), and
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drug intoxication (F10-F19, except for nicotine intoxica-
tion [F17]).
Variables for hospital visits
There are several types of hospitals and clinics in Korea
and they are divided into primary, secondary, and ter-
tiary hospitals. Primary medical clinics (i.e., public health
centers and health clinics) provide comprehensive health
care that integrates prevention and treatment and are
limited to less than 30 beds. Secondary medical institu-
tions are hospitals with more than four medical profes-
sionals and are defined by their size (30 to 100 beds).
Finally, tertiary medical institutions are advanced general
hospitals with more than 100 medical beds or more than
nine medical subjects and residents in each department.
Definitions of hospitalization and emergency room visits
If a receipt was classified as a hospitalization, costs were
associated with hospitalizations were assumed. More-
over, if a patient visited an emergency room in Korea,
the “emergency medical care cost” code may be neces-
sary. Therefore, it was possible to verify that the claim
with the associated code was, in fact, related to an emer-
gency room visit. In addition, the cost of visiting the
emergency room included all causes of visit, without dis-
tinguishing the mental cause.
Definition of clinician specialty
In South Korea, only psychiatrists can request a psychiatric
interview fee. Therefore, if patients ever had been billed a
psychiatric interview charge, that receipt was deemed to be
from a psychiatrist. The code for psychiatric interview
charges included all codes related to family therapy, enter-
tainment therapy, psychotic social work, and personal psy-
chotherapy expenses (NN011–3, NN021–3, NN031–2,
NN040, NN071–2, NN090, NN100, NN100020, NN111–
4). The interview charge is differrent depending on the time
of the psychiatrist has interviewed. And in 2018, the insur-
ance system in Korea has changed so that the difference in
interview costs over time becomes even greater. Therefore,
shortening the interview with the psychiatrist reduced the
patient’s burden.
Statistical analysis
All continuous variables were presented as mean, standard
deviation, median, and interquartile range, and all categor-
ical variables were presented as numbers or percentages.
The characteristics and cost differences between non-TRD
and TRD were compared by the Wilcoxon rank sum test.
SAS Enterprise Guide (version 6.1; SAS Institute, Cary,
NC, USA) was used for statistical analysis and p-values less
than 0.05 were considered statistically significant.
Results
There were a total of 41,256,396 Koreans over 18 years
of age in 2012, of which 4.81% were prescribed antide-
pressants and approximately half of those patients were
diagnosed with depression. Moreover, 834,694 people
(2.02% of the total population) were considered to have
PTD, while 34,812 patients were diagnosed with TRD,
accounting for 0.08% of the total population and 4.17%
of PTD patients. There were subjects (65,832; 0.16% of
the total population) who were unable to confirm the
presence of TRD because the study was terminated dur-
ing their follow-up; however, as the proportion of TRD
to PTD is about 4%, they were included in the non-TRD
group. Therefore, the total number of non-TRD patients
was 799,882, accounting for approximately 1.94% of the
total population (Fig. 1).
The average cost of medical expenses per visit for pa-
tients with PTD was 75,900 KRW (67.54 USD), and cost
directly related to depression was 127,300 KRW (113.28
USD). Of the PTD patients, 21,613 (2.59%) had suicide
codes, with associated costs estimated to be 62,800
KRW (55.87 USD), which is lower than the cost associ-
ated without suicide (77,800 KRW, 69.22 USD). The
total medical costs associated with depression gradually
increased as the type of hospital advanced (25,500 KRW,
22.58 USD in primary hospitals; 172,200 KRW, 152.46
USD in secondary hospitals; 178,700 KRW, 158.66 USD in
tertiary hospitals). This pattern was also observed in the
medical costs associated with depression codes. Psychia-
trists found that the overall cost associated with PTD was
consistent with the costs based on depression codes (96,
100 KRW, 85.50 USD); however, in the group of patients
treated by non-psychiatrists, the costs associated with de-
pression were increased, compared to the total cost (71,
500 KRW, 63.61 USD in total costs and 164,800 KRW,
146.62 USD with depression code) (Table 1).
When analyzing the utilization of medical services, in
TRD patients compared to non-TRD patients, more out-
patient visits occurred in depressive episodes (95.2 versus
15.9), emergency room visits (4.7% versus 0.6%), hospitali-
zations (3.0 times per patient and 1.7 times per patient),
and longer hospitalizations (63.4 days versus 28.9 days).
The total medical costs per person for TRD and non-TRD
patients were 6,610,500 KRW (5859.33 USD) and 1,273,
000 KRW (1128.35 USD), respectively. Moreover, the ratio
of TRD to non-TRD costs was 5.19. In the analysis of
medical costs associated with the depression diagnosis,
the TRD group incurred costs that were approximately 5
times higher than those in the non-TRD group. When an-
alyzed in conjunction with suicide, it was confirmed that
the suicide-related rate was higher in TRD patients than
in non-TRD patients (12.95% compared to 2.14%). The
total cost associated with TRD patients was 10,539,200
KRW (9343.26 USD), while non-TRD patients averaged 4,
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Fig. 1 Patient Selection Flow
Table 1 Cost per receipt of medical utilization in total PTD (1000 KRW, 0.89USD)






mean ± SD 75.9 ± 499.4 127.3 ± 748.2 62.8 ± 345.2 77.8 ± 518.0
median (Q1, Q3) 15.0 (11.5,34.3) 29.1 (13.7,46.3) 15.0 (11.8,32.7) 15.0 (14.0,34.6)
Type of hospital
Primary 25.5 ± 58.5 34.2 ± 63.4 25.3 ± 57.2 25.5 ± 58.6
Secondary 172.2 ± 577.3 256.2 ± 706.3 159.1 ± 484.0 174.1 ± 589.7
tertiary 178.7 ± 944.5 259.9 ± 1284.6 140.0 ± 655.3 183.6 ± 975.5
Specialty of physician
Psychiatry 96.1 ± 547.7 96.1 ± 547.7 108.3 ± 428.1 94.6 ± 560.8
Non-psychiatry 71.5 ± 488.3 164.8 ± 932.5 54.5 ± 327.1 74.1 ± 508.1
hospitalization 1761.1 ± 2614.9 2097.4 ± 2968.9 1358.1 ± 1759.2 1817.0 ± 2707.7
Outpatients visit 32.4 ± 67.9 38.4 ± 64.5 30.9 ± 58.2 32.7 ± 69.2
PTD pharmaceutically-treated depression, SD standard deviation, Q1 first quartile, Q3 third quartile
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902,300 KRW (4346.01 USD), demonstrating that costs
associated with TRD were roughly 2.15 times higher than
non-TRD. Finally, costs unrelated to suicide were 5.05
times higher in TRD patients than non-TRD patients (6,
026,000 KRW [5341.73 USD] versus 1,193,700 KRW
[1058.15 USD]) (Table 2).
Upon further analysis of the costs of TRD, costs asso-
ciated with TRD were highest in primary health care
centers (5.15 times higher) than secondary and tertiary
hospitals (3.45 times higher). The difference between
prescriptions by psychiatrists and non-psychiatrists was
similar (3.74–3.88 times), and the cost of prescriptions
by psychiatrists were 0.57 and 0.59 times smaller in the
TRD and non-TRD groups, respectively. The economic
burden gap between TRD and non-TRD patients due to
hospital admissions was minimal (1.72 times); however,
the cost of outpatient visits was 5.93 times higher in the
TRD group. Finally, in the TRD group, the total costs in-
curred by psychiatrists was lower than that of non-
psychiatrists, whereas in the non-TRD group, the oppos-
ite result was obtained (Table 3).
When costs were analyzed according to age, it was
confirmed that the total cost increased in both TRD and
non-TRD patients as age increased. The costs associated
with depression were similar, except that middle-aged
patients had the highest costs in the TRD group and for
costs related to hospitalization (Table 4); however, when
the ratios within each group were examined, the propor-
tion of costs for hospitalization gradually increased as
age increased, particularly within the TRD group
(Fig. 2).
Discussion
The present study analyzed the medical costs associated
with depression using the NHI, where the majority of
the Korean population is enrolled. According to the
HIRA survey, in 2012, PTD patients accounted for ap-
proximately 2% of the total population, and 4% of which
progressed to TRD. Cost associated with depression for
one hospital visit was 127,300 KRW (113.28 USD) in
South Korea. A total of 834,694 PTD patients made an
average of 19.2 outpatient visits. Based on that, the an-
nual bill was calculated to be approximately 1.2 trillion
KRW (1.07 billion USD) for outpatient visits and 294
billion KRW (261 million USD) for hospitalizations. The
sum of outpatient and hospitalization costs was








Outpatients visits mean ± SD 95.2 ± 102.9 15.9 ± 41.3
median (Q1, Q3) 64 (28,128) 3(1,11)
ER visits number 0.7(4.7) 0.1(0.6)
Hospitalization (N, %) 17,246(49.5) 149,901(18.7)
Number of hospitalization (mean, SD) 3.0 ± 3.6 1.7 ± 1.8
Days of hospitalization
(mean, SD)
63.4 ± 145.0 28.9 ± 71.4
Medical cost
Total cost mean, SD 6610.5 ± 11,126.7 1273.0 ± 4604.7 < 0.0001 5.19
median (Q1,Q3) 3326.2(1288.67157.0) 142.0(42.9685.9)
Related depression code mean, SD 3461.6 ± 7670.8 697.7 ± 3059.4 < 0.0001 4.96
median (Q1,Q3) 1384.3(543.93182.3) 70.4(26.2258.3)
Patients with suicide code (N, %) 4508 (12.95%) 17,105 (2.14%)
Total cost mean, SD 10,539.2 ± 14,061.1 4902.3 ± 9358.5 < 0.0001 2.15
median (Q1,Q3) 6178.4(3187.711790.9) 2113.6(605.35414.7)
Related depression code mean, SD 5375.7 ± 9661.1 2138.5 ± 5714.6 < 0.0001 2.51
median (Q1,Q3) 2464.5(1115.44927.5) 559.2(152.0,1923.7)
Patients without suicide code (N) 30,304 (87.05%) 782,777 (97.86%)
Total cost mean, SD 6026.0 ± 10,496.5 1193.7 ± 4411.2 < 0.0001 5.05
median (Q1,Q3) 2955.8(1152.26458.3) 135.7(41.9628.3)
Related depression code mean, SD 3176.9 ± 7286.0 666.2 ± 2967.3 < 0.0001 4.77
median (Q1,Q3) 1255.0(501.42947.4) 68.2(25.7242.2)
TRD treatment-resistant depression, SD standard deviation, Q1 first quartile, Q3 third quartile, ER emergency room, ECT Electroconvulsive therapy
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calculated, and total amount paid by PTD patients for 1
year was 1.494 trillion KRW (1.331 billion USD), which
was substantially higher compared to other countries [7,
12] (supplementary Table 1). In the present study, it has
been demonstrated that TRD costs more than non-TRD,
which is consistent with previous results [18–21]. The
cost burden of TRD was 1.72 to 5.93 times more than
non-TRD, specifically in total medical costs, patients
without a suicide code, primary hospitals, and outpatient
visits. Results of this study are consistent with the TRD-
to-non-TRD ratio obtained in studies from other coun-
tries. In a study conducted in Japan in 2017, the TRD-
to-non-TRD ratio was approximately 3 [21]. In addition,
results of the US study showed that the TRD-to-non-
TRD ratio ranged from 2.7 to 5.0, although there were
some differences depending on the type of medical use
[28]. However, in a 2002 US study, the TRD group had
six-fold higher admission costs and 19-fold higher
depression-related costs than the non-TRD group [31];
however, previous studies have analyzed papers from
Table 3 Total cost-subtype between TRD and non-TRD (1000 KRW, 0.89 USD)
TRD Non- TRD P-value TRD/non-TRD ratio
By Type of hospital
1) Primary (N, %) 33,245 (95.50%) 598,848 (74.87%)
1) Primary (mean, SD) 1872.1 ± 2951.2 363.6 ± 1384.6 < 0.0001 5.15
2) Secondary + tertiary (N, %) 31,610 (90.80%) 519,996 (65.01%)
2) Secondary + tertiary (mean, SD) 5311.2 ± 11,023.8 1539.5 ± 5263.9 < 0.0001 3.45
By specialty of Physician
(psychiatrists vs. non-psychiatrists)
1) psychiatrists (N, %) 30,484 (87.57%) 295,638 (35.71%)
1) psychiatrists (mean, SD) 2551.6 ± 5289.3 683.0 ± 2606.3 < 0.0001 3.74
2) non-psychiatrists (N, %) 34,085 (97.91%) 709,324 (88.68%)
2) non-psychiatrists (mean, SD) 4469.5 ± 9520.2 1150.9 ± 4371.3 < 0.0001 3.88
Hospitalization, outpatients visit
1) Hospitalization (N, %) 17,246 (49.54%) 149,901 (18.74%)
1) Hospitalization (mean, SD) 6978.1 ± 12,539.9 4053.3 ± 7657.0 < 0.0001 1.72
2) Outpatients visit (N, %) 34,704 (99.69%) 770,279 (96.30%)
2) Outpatients visit (mean, SD) 3163.3 ± 4379.6 533.2 ± 219.0 < 0.0001 5.93
TRD treatment-resistant depression, SD standard deviation
Table 4 Total cost analysis by age (1000 KRW, 0.89 USD)
TRD Non-TRD P-value TRD/non-TRD ratio
PTD patients aged 18–39 (N) 8294 164,113
Total cost, won (mean, SD) 4186.4 ± 8013.9 621.9 ± 2707.2 < 0.0001 6.71
With depression code 2789.7 ± 5915.4 436.2 ± 2095.6 < 0.0001 6.40
With hospitalization (N, %) 2961 (35.70%) 18,530 (11.29%)
With hospitalization (mean, SD) 5233.5 ± 10,970.8 2750.6 ± 6448.0 < 0.0001 1.90
PTD patients aged 40–59 (N) 15,157 330,818
Total cost, won (mean, SD) 7010.9 ± 12,061.7 1151.0 ± 4621.8 < 0.0001 6.09
With depression code 3895.1 ± 838.9 677.4 ± 3157.4 < 0.0001 5.75
With hospitalization (N, %) 7545 (49.78%) 58,474 (17.68%)
With hospitalization (mean, SD) 7690.2 ± 13,547.7 3895.6 ± 8070.3 < 0.0001 1.97
PTD patients aged 60+ (N) 11,361 304,951
Total cost, won (mean, SD) 7846.0 ± 11,505.0 1755.9 ± 5293.5 < 0.0001 4.47
With depression code 3373.8 ± 776.5 860.4 ± 3363.1 < 0.0001 3.92
With hospitalization (N, %) 6740 (59.33%) 72,897 (23.90%)
With hospitalization (mean, SD) 6947.3 ± 11,923.1 4511.0 ± 7556.0 < 0.0001 1.54
TRD treatment-resistant depression, SD standard deviation
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1995 to 2000, and as the prevalence of depression has in-
creased in the last 15 years, the economic costs of depression
have increased considerably. As the prevalence of depression
rapidly increases, the cost of depression has a comparable
increase, but it is possible that TRD has a smaller increase
due to its low prevalence. Our previous study revealed that a
longer duration of depressive episodes and presence of
comorbidities were more frequent in the TRD group [23].
This might explain the higher cost in TRD.
Medical costs per receipt associated with suicide was
lower than those without a suicide code; however, when
considering groups treated by a psychiatrist, the costs as-
sociated with suicide code were higher. Additionally, the
entire medical costs related to suicide were higher than
the total medical costs in both the TRD and non-TRD
groups. This could be explained by the differing group
sizes and psychotherapy fees. Suicide codes were only ob-
served in 2.59% of PTD patients (834,694 versus 21,613
with a suicide code). Patients with suicide codes who were
treated by a non-psychiatrist may not be charged a psy-
chotherapy fee, which could yield the above results.
In the present study, differences in costs according to
the prescribing doctor’s specialty were found to be oppos-
ite in the TRD and non-TRD groups, which may be attrib-
uted to Korea’s claim system. In Korea, only psychiatrists
can charge for psychotherapy; therefore, when a patient
with depression visits a hospital, psychiatrists are allowed
to request an interview fee along with the medical pre-
scription, but non-psychiatrists can only prescribe medica-
tion for their patients. In cases of non-TRD, the difference
in the number of interviews are reflected in our present
results, as pharmacological treatments show better re-
sponses and a shorter duration of use than in TRD pa-
tients; however, because TRD can be difficult to treat with
medication, it requires higher costs and interventions as
these patients use more complex drugs for a longer period
of time. Based on the results of the present study, it would
be advantageous to refer to psychiatrists when patients do
not respond to medications prescribed by non-
psychiatrists.
There was an increase in the costs of depression by
age; specifically, the cost of hospitalization gradually in-
creased with age in the non-TRD group. However, in
the TRD group, the cost associated with depression
codes and hospitalizations was highest in middle-aged
group. This result could be interpreted in a variety of
ways. First, it is likely that the average PTD patient was
of middle age. The proportion of hospitalization costs
increased with age when the difference in the number of
people was corrected for by assessing the percentage of
the cost. Second, middle-aged patients are more likely to
actively seek treatment, as this is a relatively stable occu-
pational and economic age group, compared to other
age groups. Third, depression in old age is often not di-
agnosed as depression because it often appears as other
symptoms, such as lethargy, instead of exclusively de-
pression [32]. This leads to higher medical expenses fo-
cused on the somatic symptoms not typically associated
with depression, such as chest pain and abdominal dis-
comfort. Fourth, psychiatric medication in elderly pa-
tients should be proceeded and monitored with caution,
as the period for medication adjustments is longer and
the adverse effects due to the medication are more fre-
quent [33–35]. Fifth, depression in adolescents is often
difficult to diagnose due to hostile behaviors, such as im-
pulsivity, rather than depression [36].
The strength of this study is that it was a large, nation-
wide, cohort study of the majority of the Korean popula-
tion. As a national registry was used, it was possible to
exclude reduced reports of pharmacological prescrip-
tions. Furthermore, the accuracy of the diagnosis was in-
creased due to the use of the national registry. To the
best of our knowledge, this is the first study to analyze
the economic burden of depression in Korea from vari-
ous perspectives. Analyses of the direct medical costs
due to depression have occurred that have assessed
Fig. 2 Age related hospitalization ratio between TRD and non-TRD
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various aspects, and the redistributive aspects of social
property should be considered. Therefore, to reduce the
economic burden of depression in Korea, it can be con-
cluded that psychiatrists should be more involved in the
treatment at primary care and outpatient centers, which
provide the majority of the expenses.
However, there are several limitations to the present
study. First, in this paper, the cost was calculated based
on the 2012 data. The current economic trends may dif-
fer from those 8 years before. As described in the
Methods section, several years later, excessive medical
expenses in Korea could be reimbursed with insurance.
In this study, we analyzed data from 2012, when the re-
fund process was completed, and cost was fixed. How-
ever, in 2018, there was a big change in the system of
psychiatric interview charging. This has had a large im-
pact on the cost burden of psychiatric patients, but the
cost study has practical limitations because of the refund
system. Compared to the economic burden in this study,
if the economic burden due to changes in 2018 is ana-
lyzed in the future, the impact of those changes will be
clearer. Second, although the definitions of PTD and
TRD are limited, it is difficult to apply them in a retro-
spective evaluation of national registry data. In addition,
it is difficult to determine if the drugs prescribed based
on the definitions of PTD and TRD were actually ad-
ministered, possibly leading to an overestimated cost.
However, it is possible to overcome this limitation be-
cause these drugs are rarely prescribed once but often
repeatedly for a certain period of time, and repeated
doses of unused medicines are rare. Third, the medica-
tion regimen used was in 4-week increments, but this
may not reflect a realistic prescription. There is a ten-
dency to add antipsychotics to a mood stabilizer regimen
in Korea [37]; however, our results were confirmed with
a subsequent analysis comparing 2 week and 6 week reg-
imens. In this analysis, there was a slight difference, but
it did not affect the interpretation (Supplementary Table
2). Fourth, Korea’s billing system is different from other
countries, and depending on the diagnosis, the amount
that the medical staff can claim varies. Therefore, it is
difficult to judge whether the diagnostic code registered
in HIRA is a diagnosis that accurately reflects the condi-
tion of a patient or if a diagnosis is necessary for a
charge request. For example, there is a limited number
of patients for whom a psychiatrist can charge a fee;
therefore, receipts that do not indicate costs for psychi-
atric interviews may still have been issued by a psych-
iatrist. In this case, the cost of medical care from a
psychiatrist may be underestimated. However, in many
cases this is untrue; the present study included 98% of
the Korean population and could be protected from this
error because they were followed for roughly one year.
Fifth, for patients who were considered to have PTD
until the end of the study period, it was unclear whether
they were non-TRD or TRD; therefore, we included
these patients in the non-TRD group. We classified 7.9%
of patients who were prescribed antidepressants at the
end of the observation period as non-TRD, which could
lead to statistical error. In particular, it is possible that
some of the TRD patients should have been included as
non-TRD patients, which may result in an underestima-
tion in the difference between these groups. Patients
who were unable to clarify whether they were TRD or
non-TRD were differentiated and their PTD characteris-
tics were compared with non-TRD and TRD groups,
confirming they were generally similar to the non-TRD
group (Supplementary Table 3). Finally, in the present
study, we compared the direct medical costs through the
analysis of the medical receipts registered in the NHI;
however, the economic burden of depression is not ex-
clusively the direct medical costs. Indirect medical ex-
penses, such as leave and unemployment due to
depression, can also be an economic burden. Moreover,
according to a recent systemic review of 24 studies, in-
direct medical costs are twice as much as direct medical
costs [38]. It is a methodological limit of the present
study that only the direct costs were assessed; therefore,
future studies should attempt to elucidate some of the
indirect medical costs associated with depression. Alter-
natively, using data registered in the country prevented
recall bias and allowed for the confirmation of the cor-
rect amount without error.
In the present study, we analyzed the cost differences
between TRD and non-TRD and confirmed that the pri-
mary difference was whether they received medical treat-
ment from a psychiatrist. To better understand this
difference, it is crucial to analyze data about the charac-
teristics of depression, sex difference, and whether the
first intervention was by a psychiatrist. It would be valu-
able if the present study was repeated annually and com-
pared with other countries with a different insurance
system. Additionally, further investigation is needed to
better understand the increasing hospitalizations with
age to reduce hospitalization costs in the elderly.
Conclusions
Through the present study, it was determined that the
average cost for one visit for a patient with depression in
Korea was 127,300 KRW (113.28 USD), which is quite
socially significant. Patients with TRD are burdened with
higher medical costs than are non-TRD patients, espe-
cially when including increasing age, visiting primary
care clinics, and outpatient care as variables. The costs
associated with depression were also lower when visiting
a psychiatrist, which suggests that active treatment inter-
ventions by psychiatrists in the early stages of depression
and establishing more effective policies, such as an early-
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refer program to psychiatrists, may reduce the direct
medical care costs for depression. More in-depth ana-
lyses of the costs of depression should be performed to
help establish a better political health plan.
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